---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224156"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-05-14T20:28:56+00:00"
generated_at: "2026-05-14T20:40:45.407538+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials

## Summary
- Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.
- TPST-2003 showed 100% complete response in 15 CAR-T-naïve evaluable patients across two trials; no Grade ≥3 CRS/ICANS.
- Selected Cincinnati Children's AGCTC as lead manufacturing partner; lentiviral vector received for TPST-2003.
- Appointed Andrew Fang, Ph.D., as Head of Business Development to lead partnerships and licensing.
- Completed asset acquisition of dual-targeting CAR-T assets from Factor Bioscience and Erigen; $6M private placement closed.

## SEC filing metadata
- accession: 0001193125-26-224156
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-05-14T20:28:56+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/0001193125-26-224156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/tpst-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224156
- JSON: https://secwatch.observer/filing/0001193125-26-224156.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224156.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $27.7 million, EPS $2.53.
  - Period: the quarter ended March 31, 2026
  - Net income: $27.7 million
  - EPS: $2.53
  - Result: reported results
  source text: Net loss and net loss per share for the quarter were $27.7 million and $2.53, respectively, compared to $10.9 million and $3.16, respectively, for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/0001193125-26-224156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.